99 related articles for article (PubMed ID: 32816781)
21. 2009 ESC/ERS pulmonary hypertension guidelines and connective tissue disease.
Nakanishi N; ;
Allergol Int; 2011 Dec; 60(4):419-24. PubMed ID: 22015568
[TBL] [Abstract][Full Text] [Related]
22. Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension.
Zhuang Y; Jiang B; Gao H; Zhao W
Hypertens Res; 2014 Jun; 37(6):507-12. PubMed ID: 24646647
[TBL] [Abstract][Full Text] [Related]
23. Pulmonary capillary endothelial metabolic dysfunction: severity in pulmonary arterial hypertension related to connective tissue disease versus idiopathic pulmonary arterial hypertension.
Langleben D; Orfanos SE; Giovinazzo M; Hirsch A; Baron M; Senécal JL; Armaganidis A; Catravas JD
Arthritis Rheum; 2008 Apr; 58(4):1156-64. PubMed ID: 18383374
[TBL] [Abstract][Full Text] [Related]
24. No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers.
Spence R; Mandagere A; Harrison B; Dufton C; Boinpally R
J Pharm Sci; 2009 Dec; 98(12):4962-74. PubMed ID: 19455620
[TBL] [Abstract][Full Text] [Related]
25. The short-term role of corticosteroid therapy for pulmonary arterial hypertension associated with connective tissue diseases: report of five cases and a literature review.
Kato M; Kataoka H; Odani T; Fujieda Y; Otomo K; Oku K; Horita T; Yasuda S; Atsumi T; Ohira H; Tsujino I; Nishimura M; Koike T
Lupus; 2011 Oct; 20(10):1047-56. PubMed ID: 21676917
[TBL] [Abstract][Full Text] [Related]
26. Ambrisentan and tadalafil synergistically relax endothelin-induced contraction of rat pulmonary arteries.
Liang F; Yang S; Yao L; Belardinelli L; Shryock J
Hypertension; 2012 Mar; 59(3):705-11. PubMed ID: 22311911
[TBL] [Abstract][Full Text] [Related]
27. Dendritic Cell Subsets and Effector Function in Idiopathic and Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.
van Uden D; Boomars K; Kool M
Front Immunol; 2019; 10():11. PubMed ID: 30723471
[TBL] [Abstract][Full Text] [Related]
28. Initial dual oral combination therapy in pulmonary arterial hypertension.
Sitbon O; Sattler C; Bertoletti L; Savale L; Cottin V; Jaïs X; De Groote P; Chaouat A; Chabannes C; Bergot E; Bouvaist H; Dauphin C; Bourdin A; Bauer F; Montani D; Humbert M; Simonneau G
Eur Respir J; 2016 Jun; 47(6):1727-36. PubMed ID: 26989105
[TBL] [Abstract][Full Text] [Related]
29. Pulmonary arterial hypertension in Russia: six-year observation analysis of the National Registry.
Chazova IE; Arkhipova OA; Martynyuk TV
Ter Arkh; 2019 Mar; 91(1):24-31. PubMed ID: 31090367
[TBL] [Abstract][Full Text] [Related]
30. Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension.
D'Alto M; Badagliacca R; Argiento P; Romeo E; Farro A; Papa S; Sarubbi B; Russo MG; Vizza CD; Golino P; Naeije R
Chest; 2020 Feb; 157(2):376-383. PubMed ID: 31563498
[TBL] [Abstract][Full Text] [Related]
31. Simultaneous microdetermination of bosentan, ambrisentan, sildenafil, and tadalafil in plasma using liquid chromatography/tandem mass spectrometry for pediatric patients with pulmonary arterial hypertension.
Yokoyama Y; Tomatsuri M; Hayashi H; Hirai K; Ono Y; Yamada Y; Todoroki K; Toyo'oka T; Yamada H; Itoh K
J Pharm Biomed Anal; 2014 Feb; 89():227-32. PubMed ID: 24309556
[TBL] [Abstract][Full Text] [Related]
32. Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension.
Rhee RL; Gabler NB; Sangani S; Praestgaard A; Merkel PA; Kawut SM
Am J Respir Crit Care Med; 2015 Nov; 192(9):1111-7. PubMed ID: 26291092
[TBL] [Abstract][Full Text] [Related]
33. [Pulmonary arterial hypertension with connective tissue diseases].
Fukaya S; Yoshida S
Nihon Rinsho; 2008 Nov; 66(11):2200-4. PubMed ID: 19051743
[TBL] [Abstract][Full Text] [Related]
34. Pulmonary arterial hypertension complicating connective tissue diseases.
Hassoun PM
Semin Respir Crit Care Med; 2009 Aug; 30(4):429-39. PubMed ID: 19634082
[TBL] [Abstract][Full Text] [Related]
35. Comparison between the efficacy of combination therapy and monotherapy in connective tissue disease associated pulmonary arterial hypertension: a systematic review and meta-analysis.
Pan J; Lei L; Zhao C
Clin Exp Rheumatol; 2018; 36(6):1095-1102. PubMed ID: 29998831
[TBL] [Abstract][Full Text] [Related]
36. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension.
Gaine S; Chin K; Coghlan G; Channick R; Di Scala L; Galiè N; Ghofrani HA; Lang IM; McLaughlin V; Preiss R; Rubin LJ; Simonneau G; Sitbon O; Tapson VF; Hoeper MM
Eur Respir J; 2017 Aug; 50(2):. PubMed ID: 28818881
[TBL] [Abstract][Full Text] [Related]
37. Pulmonary hypertension in connective tissue diseases: an update.
Aithala R; Alex AG; Danda D
Int J Rheum Dis; 2017 Jan; 20(1):5-24. PubMed ID: 28205373
[TBL] [Abstract][Full Text] [Related]
38. Adverse Events in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.
Rhee RL; Gabler NB; Praestgaard A; Merkel PA; Kawut SM
Arthritis Rheumatol; 2015 Sep; 67(9):2457-65. PubMed ID: 26016953
[TBL] [Abstract][Full Text] [Related]
39. Regulatory T Cell Dysfunction in Idiopathic, Heritable and Connective Tissue-Associated Pulmonary Arterial Hypertension.
Huertas A; Phan C; Bordenave J; Tu L; Thuillet R; Le Hiress M; Avouac J; Tamura Y; Allanore Y; Jovan R; Sitbon O; Guignabert C; Humbert M
Chest; 2016 Jun; 149(6):1482-93. PubMed ID: 26836928
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of anti-endothelial cell antibodies in patients with pulmonary arterial hypertension associated with connective tissue diseases.
Li MT; Ai J; Tian Z; Fang Q; Zheng WJ; Zeng XJ; Zeng XF
Chin Med Sci J; 2010 Mar; 25(1):27-31. PubMed ID: 20449950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
